[{"id":"2d611a75-574e-482e-91b3-3bf96d4e7ace","acronym":"CATCHAML","url":"https://clinicaltrials.gov/study/NCT04318678","created_at":"2021-01-18T20:55:40.221Z","updated_at":"2025-02-25T12:27:32.189Z","phase":"Phase 1","brief_title":"CD123-Directed Autologous T-Cell Therapy for Acute Myelogenous Leukemia (CATCHAML)","source_id_and_acronym":"NCT04318678 - CATCHAML","lead_sponsor":"St. Jude Children's Research Hospital","biomarkers":" CD123 • IL3RA","pipe":"","alterations":" ","tags":["CD123 • IL3RA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rituxan (rituximab) • cyclophosphamide • fludarabine IV • mesna • CD123-CAR T cell therapy • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 07/29/2020","start_date":" 07/29/2020","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2025-02-24"}]